Published in Gene Therapy Weekly, June 29th, 2006
"Vectors derived from the autonomous MVM(p) are promising tools for the gene therapy of cancer. The validation of their in vivo anti-tumour effect is, however, hampered by the difficulty to produce high-titre stocks," wrote C. Servais and colleagues, University Libre Bruxelles. "In an attempt to increase vector titres, host cells were subjected to low oxygen tension (hypoxia)."
"It has been shown that a number of viruses are produced at...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.